As CEO of Morunda, I had the privilege of interviewing Bill Schuster, Country Manager of Viatris in South Korea. Our conversation delved into the multifaceted nature of leadership in the healthcare industry, exploring challenges, successes, and the power of authenticity.A…
REGULATORY
Additional Safety Measures for Xocova “Not Needed at This Time”: MHLW Panel
A health ministry safety panel on March 22 agreed that additional safety measures are unnecessary for Shionogi’s COVID-19 treatment Xocova (ensitrelvir) at this time, while calling for thoroughly communicating caution against its use in women who are or might be…
To read the full story
Related Article
- Xocova Given to Over 50,000 Patients in 6 Months: Shionogi
June 6, 2023
- No Additional Safety Measures Needed at this Time for Xocova: Panel
May 11, 2023
- Over 40,000 Patients Given Xocova as of April 9: Shionogi
April 18, 2023
- Estimated 37,746 Patients Given Xocova as of March 19: Shionogi
March 29, 2023
- Serious Side Effect Cases Total 8: Xocova Safety Update
March 13, 2023
- Xocova Taken by Estimated 32,270 Patients as of Feb. 19: Shionogi
February 28, 2023
- MHLW Panel Maintains Caution against Xocova Use in Women Who Might Be Pregnant
February 22, 2023
- Xocova’s Serious Side Effect Cases Total 5: Shionogi
February 13, 2023
- Estimated 21,528 Patients Given Xocova as of Jan. 22: Shionogi
January 30, 2023
- Estimated 11,867 Patients Given Xocova as of Jan. 5: Shionogi
January 16, 2023
- Shionogi Reports 2 Serious Side Effect Cases in Xocova Update
January 6, 2023
- No Add'l Safety Measures for Xocova Needed “at This Time”: MHLW Panel
December 28, 2022
- Estimated 4,640 Patients Took Xocova by Dec. 18: Shionogi
December 27, 2022
- Estimated 1,024 Patients Took Xocova in First 11 Days: Shionogi
December 13, 2022
REGULATORY
- MHLW Donates Mpox Vaccine to Congo
January 28, 2025
- LDP-OK’ed Bill for PMD Act Amendment Specifies Launch of Innovative Drug Fund
January 28, 2025
- Opposition Party Member Calls for Chuikyo Reform
January 27, 2025
- Drug Discovery Fund Not Mentioned in Ruling Party Document; All Eyes on Bill’s Review on Jan. 27
January 24, 2025
- MHLW Eyes 2 Biz Models as It Pushes Generic Industry Shakeup: Minister
January 23, 2025
A total of 43 innovative new medicines are anticipated to be approved or listed in Japan this year, according to a survey by Jiho. At the center of attention are some highly innovative, but probably ultra-expensive, gene therapies, as well…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…